1. SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. (12th June 2018) Authors: Wollenhaupt, J.; Silverfield, J.; Lee, E. B.; Terry, K.; Kwok, K.; Strengholt, S.; DeMasi, R.; Wang, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 978 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years. (9th June 2015) Authors: Wollenhaupt, J.; Silverfield, J.; Lee, E.B.; Wood, S.P.; Terry, K.K.; Nakamura, H.; Kwok, K.; Anisfeld, A.; Nduaka, C.; Wang, L. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years. (15th July 2016) Authors: Wollenhaupt, J.; Silverfield, J.; Lee, E.B.; Terry, K.K.; Kwok, K.; Lazariciu, I.; Nduaka, C.; Connell, C.A.; DeMasi, R.; Wang, L. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗